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Abstract: Doripenem (S-4661) is a new parenteral antibiotic from the carbapenem class; 
similarly to imipenem and meropenem, it has a broad-spectrum activity against Gram-positive, 
Gram-negative, and anaerobic bacteria. It is active against multiresistant Gram-negative bacilli 
such as extended-spectrum beta-lactamase-producing (ESBL) Gram-negative Enterobacte-
riaceae and nonfermentative Gram-negative bacilli including some strains of Pseudomonas 
aeruginosa that are resistant to other carbapenems. Doripenem’s chemical structure is 
similar to that of meropenem (substitution of one sulfamoxil-aminomethyl chain for the 
dimethyl-carboxyl chain), and has one 1-beta-methyl chain which provides resistance to 
dehydropeptidase-I enzyme. The clinical trials conducted so far have focused on the treatment 
of severe infections such as complicated intra-abdominal infections, complicated urinary tract 
infections and pyelonephritis, nosocomial pneumonia, and ventilator-associated pneumonia. 
Given its activity profile and the results from the clinical trials, this antibiotic may be used 
for empirical treatment of multibacterial infections produced by potentially multiresistant 
Gram-negative bacilli. In 2007, the US Food and Drug Administration approved the use 
of doripenem for the treatment of complicated intra-abdominal infections and complicated 
urinary tract infections. The European Medicines Agency has approved the use of doripenem 
for the same indications in addition to nosocomial pneumonia regardless of whether it is 
ventilator-associated or not.
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Pharmacodynamic profile
Mechanism of action
Like the other beta-lactams, doripenem inhibits bacterial cell wall biosynthesis by 
inactivating the penicillin-binding proteins (PBP), which results in bacterial cell death.1 
Doripenem has shown a marked affinity for PBP2 and 4 in strains of Escherichia coli 
MC4100, for PBP2 and PBP3 in strains of Pseudomonas aeruginosa PAO1 and 27853, 
and for PBP 1 in Staphylococcus aureus.2,3 Because these PBP are considered a funda-
mental target, the profile described above justifies the broad spectrum of the carbap-
enem against Gram-negative microorganisms. Furthermore, its greater activity against 
P. aeruginosa compared to imipenem is due to its higher affinity for PBP2 and PBP3 
in strains of this specie. Doripenem is resistant to most beta-lactamases produced 
by Gram-negative and Gram-positive microorganisms, including penicillinases and 
cephalosporinases. However, it is hydrolyzed by metallo-beta-lactamases (MBL) and 
carbapenemases. Results from an in vitro study show a greater stability of doripenem Drug Design, Development and Therapy 2009:3 174
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compared to imipenem after exposure to a human recombinant 
dehydropeptidase I.4 Although this greater stability was first 
attributed to the 1-beta-methyl group in its structure, this 
association was later ruled out, based on its lesser stability 
compared to other carbapenems that have this chemical group. 
Thus, other functional groups, the distance between them, as 
well as other factors, may play a role in the stability of these 
antibiotics in regards to dehydropeptidase I.
Antibacterial activity
In vitro studies have shown that doripenem has a spectrum 
of activity similar to that of imipenem against Gram-positive 
microorganisms, while it is similar to meropenem against 
Gram-negative microorganisms.5–7
Table 1 shows the doripenem-sensitive microorganisms 
most often involved in infections for which the carbapenem 
is indicated.1 Similarly to the others in the group, the activity 
of this carbapenem is limited against strains of methicillin-
resistant Staphylococcus aureus (MRSA), Enterococcus 
faecium, and Stenotrophomonas maltophilia. US Food 
and Drug Administration (FDA) and European Medicines 
Agency (EMEA) definitions of doripenem’s breakpoints are 
shown in Table 2.8,9
Aerobic Gram-negative microorganisms
Different studies have shown a high in vitro activity of 
doripenem against aerobic Gram-negative microorganisms 
(Table 3).6,7,10–16
One of the most extensive studies was conducted in 2003 
as part of a global microbiological surveillance program, 
and included strains from more than 70 medical centers in 
North America, South America, and Europe.10 Strains of both 
Haemophilus influenzae and Moraxella catarrhalis were 
susceptible to doripenem (minimum inhibitory concentration 
required to inhibit the growth of 90% of organisms [MIC90] 
0.25 mg/L and MIC50 0.06 mg/L for H. influenzae; MIC90 
0.03 mg/L and MIC50 0.016 mg/L for M. catarrhalis), but the 
activity was lower than that observed for meropenem.10 On the 
other hand, ertapenem’s activity was higher than doripenem’s 
against beta-lactamase-producing strains of H. influenzae.6 
Doripenem’s MIC50 and MIC90 against Enterobacteriaceae 
were 0.03–0.12 mg/L and 0.03–0.5 mg/L, respectively; 
these were similar to those observed for meropenem 
(MIC50 0.016–0.06 and MIC90 0.03–0.12 mg/L), and lower 
than those described for imipenem (MIC50  0.5–2 and 
MIC90 0.5–4 mg/L). Similarly, doripenem’s MIC50 and MIC90 
were 0.06–0.25 mg/L and 0.06–0.5 mg/L, respectively, 
in 36,614 Enterobacteriaceae isolates from more than 
60 medical centers in North America, Latin America, Europe, 
and the Asian-Pacific area.15 These results coincide with 
those from other studies in which doripenem’s MIC90 in 
Enterobacteriaceae strains was between 0.03 and 0.5 mg/L, 
with the exception of strains of Proteus mirabilis, in which 
MIC90 was 1 mg/L.5,7,12 Doripenem’s activity against strains 
Table 1 indications for which doripenem is approved as 
monotherapy and the microorganisms involved
Indication Microorganism
Complicated intra-abdominal 
infection
Escherichia coli 
Klebsiella pneumoniae 
Pseudomonas aeruginosa 
Bacteroides caccae 
Bacteroides fragilis 
Bacteroides thetaiotaomicron 
Bacteroides uniformis 
Bacteroides vulgatus 
Streptococcus intermedius 
Streptococcus constellatus 
Peptostreptococcus micros
Complicated urinary tract 
infection, including pyelonephritis
Escherichia coli 
Klebsiella pneumoniae 
Proteus mirabilis 
Pseudomonas aeruginosa 
Acinetobacter baumannii
Nosocomial pneumonia, including 
ventilator-associated pneumonia
Escherichia coli 
Klebsiella pneumoniae 
Pseudomonas aeruginosa 
Staphylococcus aureus 
Streptococcus pneumoniae 
Enterobacter cloacae 
Acinetobacter baumannii 
Haemophilus influenzae
Table 2 Breakpoints defined by FDA and EMEA
EMEA FDA
Minimum inhibitory concentration
Microorganism S R S R
Staphylococcus spp.* 1 4 – –
Enterobacteriaceae 1 4 0.5 –
Acinetobacter spp. 1 4 – –
Acinetobacter baumannii – – 1 –
Pseudomonas aeruginosa – – 2
Pseudomonas spp. 1 4 – –
Streptococcus pneumoniae 1 4 – –
Haemophilus spp. 1 4 – –
Anaerobes 1 4 1 –
Note: *From methicillin breakpoint.
Abbreviations: eMeA, european Medicines Agency; FDA, US Food and Drug 
Administration; r, resistant; S, sensitive.Drug Design, Development and Therapy 2009:3 175
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Table 3 In vitro activity of doripenem against various species of Gram-negative microorganisms
Microorganism Strains tested (n) MIC50 MIC90 Range
Acinetobacter spp. 155 0.5 4 0.016–16
Acinetobacter spp. 3844 2 8
Acinetobacter baumannii 33 0.5 16 0.03–32
Acinetobacter baumannii 2982 2 8
Aeromonas spp. 44 0.5 1 0.03–4
Aeromonas spp. 172 0.5 2
Bordetella pertussis 52 0.25 0.5 0.25–0.5
Burkholderia cepacia 20 2 8 0.12–16
Burkholderia cepacia 25 8 8 4–16
Burkholderia cepaciaa 200 8 32 0.5–256
Citrobacter spp. 136 0.03 0.06 0.008–2
Citrobacter freundii 22 0.032 0.063 0.032–0.125
Enterobacter spp. 601 0.06 0.12 0.008–4
Enterobacter spp.   AmpC 33 – 0.12 –
Enterobacter cloacae 30 0.032 0.063 0.032–0.125
Non-eSBL-producing Escherichia coli 15478 0.06 0.06 –
Non-eSBL-producing Escherichia coli 3023 0.03 0.03 0.008–1
eSBL Escherichia coli 2363 0.06 0.06 –
eSBL Escherichia coli 121 0.03 0.06 0.016–1
Beta-lactamase-negative Haemophilus influenzae 1426 0.06 0.25 0.008–2
Beta-lactamase-positive Haemophilus influenzae 398 0.12 0.25 0.008–1
Beta-lactamase-negative Haemophilus influenzae 33 0.12 1 0.015–1
Beta-lactamase-positive Haemophilus influenzae 28 0.12 0.5 0.12–1
Non-eSBL-producing Klebsiella spp. 1107 0.03 0.06 0.016–16
eSBL Klebsiella spp. 155 0.06 0.12 0.016–8
Non-eSBL-producing Klebsiella pneumoniae 5387 0.06 0.06 –
Non-eSBL-producing Klebsiella pneumoniae 26 – 0.03 –
eSBL Klebsiella pneumoniae 2444 0.06 1 –
eSBL Klebsiella pneumoniae 34 – 0.06 –
Klebsiella oxytoca 38 0.063 0.063 0.032–0.063
Non-eSBL-producing Klebsiella oxytoca 1013 0.06 0.06 –
eSBL-producing Klebsiella oxytoca 277 0.06 0.12 –
Moraxella catarrhalis 108 0.016 0.03 0.008–0.5
Morganella morganii 32 0.125 0.25 0.063–0.5
Proteus mirabilis 307 0.12 0.25 0.016–0.5
eSBL-producing Proteus mirabilis 11 0.12 0.25 0.06–0.25
Proteus vulgaris 30 0.25 0.5 0.063–0.5
indol-positive Proteae 148 0.12 0.5 0.03–1
Non-eSBL-producing Proteus mirabilis 1766 0.12 0.25 –
eSBL-producing Proteus mirabilis 129 0.25 0.5 –
Providencia rettgeri 21 0.125 0.25 0.063–1
Pseudomonas aeruginosa 829 0.5 8 0.03–16
Pseudomonas aeruginosa 9256 0.5 8 –
Pseudomonas aeruginosa r carbapenems 49 – 32 –
Pseudomonas aeruginosa r carbapenems 34 8 32 0.5–32
(Continued)Drug Design, Development and Therapy 2009:3 176
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of extended-spectrum beta-lactamase (ESBL) producing 
Enterobacteriaceae such as E. coli and Klebsiella spp. is 
similar to that observed for meropenem, and four to eight 
times higher than ertapenem’s and imipenem’s.7 Against 
strains of Enterobacter spp. doripenem and meropenem 
showed an activity eight times higher than that observed 
for imipenem and ertapenem (MIC90 0.12 mg/L vs MIC90 
1 mg/L, respectively).10 Similarly, the MIC of doripenem 
against strains of AMPc-producing Enterobacter spp. 
ranged between 0.06 mg/L and 0.5 mg/L, comparable 
to the activity of meropenem (MIC 0.03–0.25 mg/L), 
and higher than that of imipenem (MIC 0.12–2 mg/L) and 
ertapenem (MIC 0.06–1 mg/L).17 Other doripenem’s MIC 
values against imipenem-resistant Enterobacter spp. isolated 
from bacteremia have been reported (doripenem MIC 
0.03–2 mg/L, meropenem MIC 0.06–8 mg/L, ertapenem MIC 
0.015–64 mg/mL).18
In contrast, against strains of P. mirabilis, Serratia spp.   
and Salmonella spp. doripenem’s MIC90 was higher than that 
observed for meropenem and ertapenem, and lower than that 
observed for imipenem.10 Several studies have concluded that 
the activity of doripenem is comparable to that of meropenem 
against strains of P. aeruginosa and Acinetobacter spp.10,11,19 
Thus, doripenem and meropenem were the most active 
carbapenems against strains of these bacteria, displaying a 
higher activity than imipenem and ertapenem.6,10 Additionally, 
doripenem’s activity was similar to that of meropenem 
against imipenem-sensitive strains of P. aeruginosa, with a 
MIC90 of 2 mg/mL, and a MIC50 of 0.25 mg/L;19 its activity 
was higher than that of all other carbapenems against 
strains of P. aeruginosa that were resistant to imipenem.7 
Doripenem’s MIC was 4 mg/L for most imipenem-resistant 
P. aeruginosa isolates from bacteremia included in other 
study.20 Similarly, doripenem showed a high activity against 
strains of P. aeruginosa that were resistant to ceftazidime, 
ciprofloxacin, imipenem or gentamicin; the activity was 
comparable to that of meropenem, and higher than that of 
the other antibiotics tested.11,21 As expected, doripenem, like 
the other carbapenems, had no activity against strains of 
carbapenemase-producing Gram-negative bacilli.17
Doripenem’s activity is superior to that of imipenem 
and meropenem in A. baumannii clinical isolates producing 
the OXA-58 carbapenemase (doripenem’s MIC50 and 
MIC90 of 4 and 8 mg/L, respectively, and imipenem’s 
and meropenem’s MIC50 and MIC90 of 16 and 64 mg/L, 
respectively).22
Aerobic Gram-positive microorganisms
According to various studies conducted, doripenem’s activity 
against Gram-positive microorganisms is comparable to 
Table 3 (Continued)
Microorganism Strains tested (n) MIC50 MIC90 Range
MBL-producing Pseudomonas aeruginosa 15 32 32 4–32
Pseudomonas aeruginosa S imipenem 83 0.25 2 0.063–8
Pseudomonas aeruginosa r imipenem 32 8 8 2–16
Pseudomonas aeruginosa r ceftazidime 39 2 8 0.063–16
Pseudomonas aeruginosa R ciprofloxacin 16 0.5 8 0.125–8
Pseudomonas aeruginosa r gentamicin 37 0.5 8 0.063–16
Pseudomonas aeruginosaa 82 0.25 2 0.25–256
Mucoid Pseudomonas aeruginosaa 200 8 32 0.25–512
Non-mucoid Pseudomonas aeruginosaa 200 8 64 0.25–512
Other Pseudomonas spp. 438 0.5 4 –
Salmonella spp. 530 0.06 0.06 0.016–0.25
Serratia spp. 187 0.12 0.25 0.03–1
Serratia marcescens 30 0.125 0.25 0.063–4
Shigella spp. 161 0.03 0.06 0.016–0.06
Stenotrophomonas maltophilia 1269 8 8 –
Stenotrophomonas maltophilia 80 16 16 1–16
Notes: aStrains isolated from patients with cystic fibrosis. Data from Fritsche et al,10 Tsuji et al,11 Jones et al,6,7,12 Traczewski et al,13 Chen et al,14 Mendes et al,15 Castanheira et al.16
Abbreviations: AmpC, ampicillinases; eSBL, extended-spectrum beta-lactamases; MBL, metallo-beta-lactamases; MiC, minimum inhibitory concentrations; r, resistant; 
S, sensitive.Drug Design, Development and Therapy 2009:3 177
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imipenem’s and superior to meropenem’s and ertapenem’s 
(Table 4).6,10,11,23
Doripenem proved to be more powerful than other 
carbapenems against strains of oxacillin-sensitive S. aureus 
(OSSA), with a MIC90 and a MIC50 of 0.06 mg/L, and against 
oxacillin-sensitive coagulase-negative Staphylococcus spp. 
with at MIC90 of 0.06 mg/L and a MIC50 of 0.03 mg/L,6,10 
while for oxacillin-resistant strains, the MIC90 ranged 
between 4 mg/L for strains of S. epidermidis, and 32 mg/L 
for strains coagulase-negative Staphylococcus spp. These 
values were comparable to those observed with imipe-
nem, and lower than those observed with meropenem 
and ertapenem.5,19 Doripenem’s activity against strains of 
Enterococcus faecalis and Enterococcus spp. other than 
E. faecium was lower than imipenem’s, and higher than that 
observed with meropenem or ertapenem.10 Thus the MIC90 
for doripenem was 8 mg/L, vs 4 mg/L for imipenem, 16 mg/L 
for meropenem, and 8 mg/L for ertapenem, while the 
MIC50 for doripenem was 4 mg/L, vs 1 mg/L for imipenem 
and 8 mg/L for meropenem and ertapenem. Similar results 
were obtained in another study with strains of E. faecalis, 
but a lower MIC90 was observed for imipenem, 2 mg/L.5 
Like the rest of the carbapenems, doripenem showed 
little activity against strains of E. faecium, with values of 
MIC90 and MIC50 over 16 mg/L.5,6,10 These values were 
independent from the pattern of vancomycin-resistance 
showed in the strains examined. Doripenem’s activity 
was comparable to that of imipenem against strains of 
Streptococcus in the viridans group, with MIC90 of 0.5 mg/L 
and MIC50 of 0.03 mg/L.10 Based on the MIC50, the activity 
observed was twice as high as that of meropenem (MIC50 
0.06 mg/L, MIC90 0.5 mg/L), and four times as high as that of 
ertapenem (MIC50 0.12 mg/L, MIC90 1 mg/L). Additionally, 
doripenem showed an excellent activity against strains 
of beta-hemolytic Streptococcus spp., Streptococcus 
pyogenes, and Streptococcus agalactiae, with MIC90 of 
0.03 mg/L and MIC50  0.008 mg/L.5,10 The activity of the 
various carbapenems was comparable against strains of 
Streptococcus pneumoniae, but differences were observed 
depending on the penicillin-resistance pattern.5 Thus, the 
MIC50 against penicillin-sensitive strains was 0.008 mg/L 
for doripenem, meropenem, and imipenem, and 0.015 mg/L 
for ertapenem, while in penicillin-resistant strains, it was 
0.5 mg/L, except for ertapenem, whose MIC was 1 mg/L.
Table 4 In vitro activity of doripenem against various species of Gram-positive microorganisms
Microorganism Strains tested (n) MIC50 MIC90 Range
Enterococcus faecalis (1206) and other non-faecium species (70) 1276 4 8 0.008–16
Enterococcus faecalisa 45 4 16 0.015–32
Enterococcus faecium 198 16 16 0.03–16
Staphylococcus aureus S oxacillin 2705 0.06 0.06 0.008–4
Coagulase-negative Staphylococcus S oxacillin 297 0.03 0.06 0.008–8
Staphylococcus aureus S methicillin 75 0.03 0.06 0.03–0.06
Staphylococcus aureus r methicillin 75 0.5 8 0.06–32
Staphylococcus aureus i vancomycin 4 16 16 0.06–16
Streptococcus pneumoniae 885 0.016 0.5 0.008–1
Streptococcus pneumoniae S penicillin 20 0.015 0.015 0.015
Streptococcus pneumoniae i penicillin 10 0.03 0.25 0.015–0.5
Streptococcus pneumoniae r penicillin 23 0.5 1 0.25–2
Streptococcus pneumoniae S penicillin 25 0.008 0.008 0.004–0.016
Streptococcus pneumoniae r penicillin 25 0.25 0.5 0.016–2
Streptococcus viridans group 140 0.03 0.5 0.008–16
Streptococcus viridans group S penicillin 23 0.03 0.06 0.015–0.12
Streptococcus viridans group i penicillin 13 0.25 0.5 0.015–2
Streptococcus viridans group r penicillin 13 2 4 0.25–4
Beta-hemolytic Streptococcus 397 0.008 0.03 0.008–0.25
Streptococcus pyogenes 42 0.004 0.004 0.004
Streptococcus agalactiae 32 0.016 0.032 0.016–0.032
Notes: aincludes four van A strains and two van B strains. Data from Fritsche et al,10 Tsuji et al,11 Jones et al,6,7 Brown et al.23
Abbreviations: i, intermediate sensitivity; MiC, minimum inhibitory concentrations; r, resistant; S: sensitive.Drug Design, Development and Therapy 2009:3 178
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Anaerobic microorganisms
Doripenem has shown a high in vitro activity against a large 
number of anaerobic microorganisms (Table 5), with a MIC 
ranging, in various studies, from 0.015 to 32 mg/L.6,24–28
The highest MIC values were obtained against strains 
of Clostridium difficile, but they were lower than the MICs 
obtained with ertapanem and meropenem.24,27 Doripenem has 
shown a high activity against strains of Bacteroides fragilis, 
with MIC50 and MIC90 values of 0.25 mg/L and 0.5 mg/L, 
respectively.6
Mechanisms of resistance
Various resistance mechanisms to carbapenems have been 
identified; they include the loss of porin OprD, the expression 
of efflux systems, the production of carbapenemases, and the 
alteration of certain penicillin-binding proteins (PBPs).29
Table 5 In vitro activity of doripenem against various species of anaerobic microorganisms
Microorganism Strains tested (n) MIC50 MIC90 Range
Anaerococcus spp.a 22 0.015 0.06 0.015–0.5
Bacteroides caccae 16 0.5 2 0.25–4
Bacteroides distasonis 15 0.5 2 0.125–2
Bacteroides fragilis 26 0.25 0.5 0.12–1
Bacteroides fragilis 81 0.5 1 0.25–16
Bacteroides fragilis 198 0.5 1 0.125–16
Bacteroides ovatus 20 0.5 1 0.12–2
Bacteroides ovatus 35 0.5 2 0.25–4
Bacteroides thetaiotaomicron 42 0.5 1 0.12–2
Bacteroides thetaiotaomicron 78 0.5 1 0.125–8
Bacteroides uniformis 21 0.5 1 0.125–1
Bacteroides vulgatus 31 0.5 2 0.125–2
Bilophila wadsworthia 21 0.12 0.12 0.03–0.12
Clostridium difficile 110 1 2 0.5–4
Clostridium perfringensa 10 0.015 0.03 0.015–0.03
Clostridium perfringens 13 0.06 0.125 0.06–0.125
Corynebacterium amycolatuma 14 0.5 2 0.06–32
Corynebacterium spp. group I (C. aurimucosum,  
C. jeikeium, C. minutissimum, C. urealyticum)a
14 1 8 0.25–32
Corynebacterium spp. group i (C. striatum,  
C. accolens, C. simulans, C. xerosis)a
18 0.125 0.25 0.015–0.25
Finegoldia magnaa 30 0.06 0.125 0.015–0.25
Fusobacterium spp. 15 0.031 1 0.03–1
Peptoniphilus asaccharolyticusa 20 0.015 0.06 0.015–0.125
Peptostreptococcus spp.a 17 0.06 0.25 0.03–0.25
Peptostreptococcus magnus 21 0.0625 0.125 0.0156–0.5
Porphyromonas spp. 20 0.031 0.5 0.03–4
Prevotella spp. 20 0.12 0.25 0.03–1
Prevotella bivia 28 0.25 1 0.125–4
Prevotella intermedia/nigrescens 10 0.031 0.062 0.03–0.06
Prevotella oris/buccae 10 0.12 0.5 0.03–0.5
Propionibacterium acnesa 14 0.06 0.125 0.03–0.25
Propionibacterium acnes 18 0.06 0.06 0.06–0.06
Propionibacterium spp. 13 0.06 0.06 0.06–0.06
Sutterella wadsworthensis 12 4 8 0.06–32
Notes: aStrains isolated from patients with infected diabetic foot wound. Data from Goldstein et al,26 Jones et al,6,7 wexler et al,24 Hecht et al,27 Mikamo et al,28 Snydman et al.25Drug Design, Development and Therapy 2009:3 179
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In the specific case of doripenem, treatment with the 
carbapenem has been associated with a reduced potential of 
selection of resistance in strains of P. aeruginosa, for which 
reason it may be a good alternative to cover infections by 
these microorganisms.7,30 With regard to the loss of porins, 
an experiment with five mutant strains selected after expo-
sure to doripenem identified the loss of OprD in some of the 
strains, which produced cross-resistance only with the other 
carbapenems.30
Another study had the objective of determining the spe-
cific substrates of three different efflux systems, MexAB-
OprM, MexCD-OprJ, and MexXY-OprM, in strains of 
P. aeruginosa.31 For this purpose, three isogenic mutants were 
constructed, each constitutively producing mostly one of the 
three efflux systems and neither of the other two; the isogenic 
mutants lacking this mechanism were then compared. All 
efflux pumps expelled different antibiotics, including quino-
lones, macrolides, tetracyclines, lincomycin, chloramphenicol, 
most penicillins and cephalosporins, meropenem, and doripe-
nem. However, polymyxin B and imipenem were not affected. 
Another study included two strains of B. fragilis, WAL 108 
and WAL 219;32 its objective was to determine the potential of 
various antimicrobials, including doripenem, to select mutant 
strains of multi-resistant B. fragilis by overexpression of bmeB 
efflux pumps. Ampicillin, doripenem, imipenem, levofloxacin, 
and metronidazole selected multiresistant mutants derived 
form both strains. All mutant strains derived from WAL 219, 
except those selected with doripenem, showed more than 
twice an overexpression of one or more of the bmeB genes 
compared to strains selected from WAL 108. Although the 
strains derived from WAL 219 after exposure to doripenem 
did not overexpress any bmeB efflux pump, they did show 
multidrug resistance, which means that there is overexpression 
of other genes that codify other efflux pumps.
Like the rest of the carbapenems, doripenem’s activity is 
decreased in the presence of carbapenemases produced by 
strains of certain microorganisms.17 Thus, the MIC increased 
from 0.25–1 µg/mL to 16–64 µg/mL in strains of metallo-beta-
lactamase (MBL)- or OXA-type carbapenemase-producing 
Acinetobacter spp. and from 8 µg/mL to more than 64 µg/mL 
in strains of IMP-, KPC-, and SME-type beta-lactamase-
producing Klebsiella spp. and Serratia spp. However, based on 
the sensitivity displayed by IMP-1 and NMC-A beta-lactamase-
producing strains of E. coli by transconjugation, resistance to 
carbapenems might require other additional mechanisms.
Although the enzymes described above have been more 
often implicated in the inactivation of carbapenems, these 
antibiotics did not behave like inactivators of the enzyme 
CTX-M-14 produced by strains of E. coli TUM1121.33 
However, the enzyme’s catalytic activity was very reduced, 
according to the values obtained for kinetic parameters at 
steady state.
Although doripenem has shown a high affinity for all 
types of PBP in strains of penicillin-sensitive S. pneumoniae, 
it has been reduced in resistant strains, especially when 
PBP2x and PBP2b are affected.34
Associating doripenem with an aminoglycoside seems 
to reduce the potential selection of strains that are highly 
resistant to carbapenem, according to the results observed 
after exposing six strains of P. aeruginosa from patients with 
bacteremia to doripenem or to the association of carbapenem 
and gentamicin.35
The various resistance mechanisms described above come 
mostly from in vitro studies with doripenem. For this reason, 
more studies are required in order to learn more about these 
mechanisms more precisely, and to understand their effects 
on routine clinical practice.
Bactericidal activity
Doripenem has shown an excellent bactericidal activity 
against aerobic and anaerobic microorganisms, comparable 
to that of the other carbapenems, and better than that of 
ceftazidime. After 48 hours of exposure to doripenem at a 
concentration of twice the MIC (2XMIC), a 99.9% eradica-
tion of strains of seven anaerobic species was observed.36 In 
strains of P. aeruginosa, the exposure to doripenem achieved 
a higher elimination when the concentration of the antibiotic 
was 10 times the bacterium’s MIC.37 In a computerized phar-
macokinetics simulation model, the exposure to doripenem, 
imipenem, and meropenem for two hours reduced the num-
ber of CFU/mL more than 2 log10, while ceftazidime only 
achieved a similar reduction with an exposure of over four 
hours. Experimental models have yielded similar results.28
Pharmacokinetic/pharmacodynamic 
parameters
The integration of pharmacokinetic/pharmacodynamic 
parameters (PK/PD) derived from nonclinical models with 
pharmacokinetic data from phase I studies may be useful 
for the purpose of optimizing antibiotic dosage regimens 
in phase II and III studies.38 In the case of doripenem, one 
study39 used the PK/PD parameters obtained in another study 
with a mouse-thigh infection model, in which the mean value 
of parameter T  MIC associated with 1 log10 and 2 log10 
reductions in CFU/thigh were 21.1 ± 8.9% and 27.3 ± 11.9% 
for strains of S. pneumoniae, 32.3 ± 6.7% and 35.4 ± 5.0% Drug Design, Development and Therapy 2009:3 180
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for strains of S. aureus, and 36.1 ± 7.4% and 43.3 ± 7.1% for 
Gram-negative bacilli, respectively.40 Additionally, by using 
the pharmacokinetic data from phase I studies, and applying 
the Monte Carlo simulation, the probability of obtaining a 
T  MIC over 35% was determined for different dosage 
regimens of doripenem (doses of 250, 500, 750, 1,000, 
2,000, and 3,000 mg; intervals of 6, 8, 12, and 24 hours, and 
duration of infusion of 1 to 6 hours, and 24 hours). Accord-
ing to the results, when the MIC was 1 mg/L, the probability 
of obtaining a T  MIC of 35% was observed with all the 
doses studied (250–1,000 mg) administered every eight 
hours, irrespective of the duration of the infusion. On the 
other hand, when the MIC was 2 mg/L, the probability of 
obtaining the objective value of the PK/PD parameter was 
similar with doses of 500 mg or higher administered every 
eight hours in one-hour infusions. A regimen of 500 mg every 
eight hours in one-, two-, and three-hour infusions resulted in 
a 0.99, 1, and 1 probability of obtaining a value of T  MIC 
of 35%, respectively. Finally, when MIC was 4 or 8 mg/L, 
the probability of obtaining a T  MIC of 35% was higher 
when the same daily doses of doripenem were used, but over 
a longer infusion time. When MIC was 4 mg/L a regimen 
of 500 mg every eight hours in three-, four- or five-hour 
infusions resulted in a 1, 1, and 0,99 probability of obtaining 
a T  MIC of 35%, respectively. Similarly, a regimen of 
1, 000 mg every 12 hours in four-, five- or six-hour infusions 
resulted in a probability of obtaining a T  MIC of 35% of 
1 in all cases. Additionally, a regimen of 1,000 mg every 
eight hours in one-, two- or three-hour infusions resulted in a 
probability of obtaining a T  MIC of 35% of 0.99, 1, and 1, 
respectively. Finally, a regimen of 1,000 mg every 24 hours 
in 24-hour infusion led to a probability of 0, but 2,000 mg 
or 3,000 mg led to a probability of obtaining a T  MIC of 
35% of 0,98 and 1, respectively. On the other hand, when 
MIC was 8 mg/L, a regimen of 1,000 mg every eight hours in 
three-, four- or five-hour infusions resulted in 1, 1, and 0.99 
probability of obtaining a T  MIC of 35%, respectively. 
However, a regimen of 1,000, 2,000 or 3,000 mg every 
24 hours in 24-hour infusion led to a 0, 0, 0,46 probability 
of obtaining a T  MIC of 35%, respectively.
Thus, by prolonging the infusion time, the administration 
of similar doses may be effective in the treatment of 
microorganisms with different doripenem’s MICs.
Similarly to the study above, another study with a 
mouse-thigh infection model with strains of P. aeruginosa 
used the doripenem dosages that allowed an approximation 
to the T  MIC simulated in human beings, based on 
pharmacokinetic parameters from 24 healthy individuals1 
after the administration of 500 mg every eight hours, either 
in a one-hour or a four-hour infusion.41 By administering the 
antibiotic in a one-hour infusion, the achieved reduction in the 
bacterial load was approximately 3 log10 CFU/mL when the 
MIC was between 0.125 mg/L and 2 mg/L, with a T  MIC 
between 42.5% and 100%; the results varied widely when the 
MIC was 4 mg/L or 8 mg/L, with T  MIC values of 20% 
and 30%, respectively. Thus, bacterial growth was observed 
in two of the eight strains that showed these MIC values, one 
of 4 mg/L, and the other of 8 mg/L. Finally, bacterial growth 
was observed in the strains with a MIC of 16 mg/L, with a 
T  MIC value of 10%. On the other hand, by administering 
the antibiotic in a four-hour infusion, the efficacy obtained was 
similar to that observed with the one-hour administration, when 
the MIC was 2 mg/L, with a T  MIC value between 42.5% 
and 70%. Surprisingly, the bacterial growth observed was of 
approximately 1 log10 CFU/mL in two of the four strains with a 
MIC of 4 mg/L, with a T  MIC value of 52.5%, an unexpected 
result. However, the decrease in the bacterial load observed 
in the two remaining strains was –1.5 to –2.5 log10 CFU/mL, 
with a T  MIC similar to that of the other two strains, ie, 
52.5%. This decrease was greater than that observed with a 
one-hour infusion. Finally, a global growth was observed in the 
bacterial density when the MIC was between 8 and 16 mg/L, 
but MIC was not surpassed at any time (T  MIC = 0%). 
Thus, exposure to T  MIC values  40% resulted in a more 
effective bactericidal activity, while values of this parameter 
between 20% and 30% led to more variable results. Similar 
values for the T  MIC parameter of doripenem were reported 
in a study that used an in vitro PK/PD against three strains of 
P. aeruginosa.42 Thus, steady state was reached with values of 
this index of 25%, 23.9%, and 39.8% for each of the strains, 
a bacterial eradication of 2 log CFU/mL was obtained with 
values of 28.1%, 29.5%, and 49.6%, and 90% of maximum 
bacterial eradication was obtained with T  MIC values of 
36.5%, 46.8%, and 80.7%. This study, along with a prior 
study that used a pharmacodynamic model for analyzing 
bactericidal kinetic parameters in vitro,43 did not take into 
account the possible role of certain factors that appear only in 
vivo and which may affect the antimicrobial agent’s activity, 
such as the immune system. With the purpose of attenuating 
this limitation, another study used a simulation strategy 
and a PK/PD model to simulate doripenem’s, imipenem’s, 
and meropenem’s bactericidal profile in a murine model of 
P. aeruginosa lung infection.44 The results showed a good 
estimation of the bacterial eradication curves obtained by the 
model when applied to animals, which may be useful in the 
future design of therapeutically useful dosage regimens.Drug Design, Development and Therapy 2009:3 181
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The results of another study with 100 strains of P. aeruginosa 
showed a higher probability of reaching a T  MIC value 
of 25% (T  MIC 25%) and 40% (T  MIC 40%) with 
doripenem vs imipenem and meropenem, regardless of the 
dosage regimen used.45 Thus, the probability of achieving 
the T  MIC 25% and T  MIC 40% for doripenem with 
the 500 mg every eight hours in a half-hour infusion regimen 
was 77.2% and 54.9%, respectively, when the dilution method 
used to obtain the MIC was the serial twofold dilution method; 
these values were 80.2% and 54.7% respectively, when an 
integrated concentration method was used to obtain the 
MIC. Similarly, the probability of obtaining T  MIC 25% 
and T  MIC 40% for doripenem with the 250 mg every 
eight hours in a half-hour infusion scheme was 60.6% and 
37.4%, respectively, when the dilution method used to 
obtain the MIC was the serial twofold dilution method, while 
these values were 60.4% and 36.8%, respectively, when 
an integrated concentration method was used. Population 
pharmacokinetic modeling was conducted using drug 
concentration data in plasma and urine from 18 patients 
with urinary tract infection and prostatitis.46 Based on this 
pharmacokinetic model, a Monte Carlo simulation predicted 
the probabilities of attaining T  MIC 40% in plasma and 
defined the PK/PD breakpoints. The highest MIC at which the 
probability of target attainment in plasma was 90% varied 
with creatinine clearance (CL) and doripenem regimen. The 
value for 500 mg every eight hours with a creatinine CL of 
80 mL/min corresponded to those for 250 mg every eight 
hours with a creatinine CL of 40 mL/min and 250 mg every 
12 hours with a creatinine CL of 20 mL/min, all of them 
administered in one-hour infusion. The aim of a recent study 
was to analyze the urinary bactericidal titers (UBTs) and 
24-hour area under the UBT-versus-time curve (AUBT) of 
intravenous doripenem (500 mg every eight hours) versus 
those of intravenous levofloxacin (250 mg every 24 hours) 
in patients with complicated urinary tract infections or 
pyelonephritis.47 For the selected clinical strains, median 
UBTs and median 24-hours AUBTs of doripenem ranged 
between 1.5 and 65,536 and between 224 and 909,312, 
respectively. These values were significantly higher than 
those of levofloxacin, with the exception of S. aureus 
1134684 (median UBTs 0–128, median 24-hour AUBTs 
0–2,208). Eight microbiological failures were observed, 
three after doripenem treatment and five after levofloxacin 
treatment. In the levofloxacin group, microbiological failures 
were observed only in patients with AUBT values of 152 or 
lower, whereas no correlation between treatment failure and 
AUBT level was found in the doripenem group.
The clinical safety and efficacy of some of the dosing 
regimens have been confirmed in phase III clinical trials.48 
However, phase III clinical trials of doripenem in hospital-
acquired pneumonia at a dose of 1,000 mg infused over 
four hours every eight hours are undergoing clinical 
evaluation.
Pharmacokinetic profile
Distribution
The administration of a single 500 mg dose of doripenem to 
24 healthy subjects by intravenous infusion over one hour 
was associated with a mean maximum concentration (Cmax) 
of 23 ± 6.6 µg/mL and an AUC of 36.3 ± 8.8 µg⋅h/mL.1 In 
another study, the administration of a single 500 mg dose 
of radiolabeled doripenem to eight healthy individuals in a 
one-hour infusion produced a Cmax of 22.9 ± 2.37 µg/mL, 
which was reached in a period (Tmax) of 1.02 hours.26 Also, 
AUC0–∝ was 31.8 ± 4.50 µg⋅h/mL. Doripenem was the main 
plasma component, and represented 80.7% of the AUC0–∝ 
for total plasma radioactivity.
The binding of doripenem to plasma proteins is estimated 
to be 8.1%, regardless of the plasma concentrations obtained.1 
The mean distribution volume is 16.8 L (range: 8.09–55.5) in 
healthy individuals once steady state has been reached; this 
value is similar to the extracellular fluid volume (18.2 L).
The administration of doripenem to 10 abdominal surgery 
patients yielded an AUC0–∝ of 59.3 ± 7.2 mg⋅h/L in serum, 
and of 49.3 ± 6.5 mg⋅h/L in peritoneal exudate, with a ratio 
of AUC0–∝ exudate/AUC0–∝ serum of 0.84 ± 0.13.49 Despite 
these values, T  MIC yielded a slightly higher value 
in peritoneal exudate compared to serum, but significant 
differences were seen only when the MIC was 1 or 4 mg/L. 
Thus, T  MIC in the exudate compared to that in serum was 
78.2 ± 10.6% vs 73.6 ± 12%, respectively when the MIC was 
1 mg/L; 41.5 ± 7.3% vs 37.0 ± 6.3% respectively, for a MIC 
of 4 mg/L; and 13.1 ± 4.0% vs 12.7 ± 1.7% respectively, for 
a MIC of 16 mg/L. This fact may be explained by the small 
difference (only 0.2 hours) observed in reaching the Tmax 
in both compartments; for this reason it has been thought 
that the concentration in the exudate would be higher than 
in serum once 0.81 hours had elapsed after administration. 
In addition to the peritoneal level, doripenem has also shown 
an ability to penetrate other tissues and/or fluids, according 
to studies in animal models (Table 6).50
Metabolism and excretion
Doripenem-M-1, which has a dicarboxylic acid structure, is 
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have been identified: the glycine- and taurine-conjugates of 
doripenem-M-1, and the oxidized metabolite of doripenem-M-1. 
However, these three derivates represented less than 3% when 
a single 500-mg dose of doripenem was administered to 
healthy individuals.51 Doripenem-M-1’s Cmax and AUC0-∝ 
were 1.56 ± 0.24 µg/mL and 4.98 ± 0.389 µg⋅h/mL on average, 
which represent 6.8% and 15.7% of doripenem’s Cmax and 
AUC0-∝, while t ½ was 2.54 ± 0.264 hours. In a study using 
radiolabeling, doripenem-M-1 contributed 12.7% of the 
AUC0-∝ plasma total-radioactivity. Additionally, the percentage 
of doripenem-M-1’s AUC compared to doripenem’s AUC 
was 18 ± 7.2% following the administration of a single dose 
of 500 mg or 1 g to healthy individuals.1
Table 7 shows several pharmacokinetic parameters of 
doripenem in healthy patients and in patients undergoing 
abdominal surgery. The elevated CL, along with the 
reduction in excretion of the carbapenem after administra-
tion with probenecid, suggests that doripenem undergoes 
both glomerular filtration and active tubular secretion. 
Approximately 70% of the antibiotic was excreted unchanged 
in urine within 48 hours after administration of a single 
500-mg dose to healthy individuals, while 15% was excreted 
as a metabolite.1 In another study, 93.4% and 95.3% of 
radioactivity was recovered in urine during the first 12 hours 
and at seven days, respectively, following the administration 
of a single 500-mg dose of radiolabeled doripenem in a 
one-hour infusion to eight healthy individuals.51 On the 
other hand, fecal excretion of doripenem was also observed, 
but it represented only 0.72% of the dose administered. 
Additionally, the total amount of drug excreted in urine (Ae) 
was 394.1 mg seven days after administration for doripenem, 
which represented 78.7% of the dose, while the Ae for 
doripenem-M-1 was 92.9 mg, which represented 18.5% of 
the dose. A total of 487 mg (97.2%) of the administered dose 
of doripenem was recovered in urine, either unchanged or as 
doripenem-M-1. Despite the fact that recovery in urine was 
complete during the first 24 hours after administering the 
dose, excretion occurred mostly during the first four hours. 
Renal CL of doripenem and doripenem-M-1 was 12.5 L/h 
and 18.9 L/h, respectively.
Table 6 Plasma and different tissues concentrations following the administration of 500 mg of doripenem
Antibiotic Time (min) Plasma (µg/mL) Liver (µg/g) Kidney (µg/g) Lung (µg/g) Spleen (µg/g) Heart (µg/g)
Doripenem 5 46.9 ± 2.3 14.5 ± 1.1 42.2 ± 6.6 11.3 ± 2.5 5.71 ± 0.86 7.77 ± 0.33
15 16.9 ± 3.7 14.8 ± 2.9 16.4 ± 1.8 3.47 ± 0.43 0.99 2.52 ± 0.19
60 0.97 ± 0.18 2.04 ± 1.19 0.80 ND ND ND
Notes: Adapted from Hori T, Nakano M, Kimura Y, Murakami K. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to 
laboratory animals. In Vivo. 2006; 20(1):91–96.
Abbreviation: ND, not detected.
Table 7 Pharmacokinetic characteristics of doripenem in healthy patients and in patients who underwent abdominal surgery
Dosage regimen 500 mg single  
dose
500 mg single  
dose
500 mg pre-surgery  
and 500 mg/8 h post-surgery
infusion time (h) 1 1 0.5
Study population 24 healthy subjects 8 healthy subjects 10 patients who underwent 
abdominal surgery
Cmax (µg/mL) 23 ± 6.6 22.9 ± 2.37 46.9 ± 7.4
Tmax (h) – 1.02 (1.00–1.02) 0.5
AUC (µg⋅h/mL) 36.3 ± 8.8 31.8 ± 4.50 59.3 ± 7.2
PPB (%) 8.1% – –
vss (L) 16.8 (8.09–55.5) 24.8 ± 5.80 11.0 ± 1.7
t1/2 (h) 1 1.07 ± 0.125 –
Kidney Cl (L/h) 10.8 ± 3.5 12.5 –
Total Cl (L/h) 15.9 ± 5.3 16 ± 2.23 8.56 ± 1.14
Notes: Data from Doribax® (doripenem for injection) package insert,1 Cirillo et al,51,52 ikawa et al.49
Abbreviations: AUC, area under the curve; Cl, clearance; Cmax, maximum concentration; PPB (%), plasma protein binding; t1/2, serum half-life; Tmax, time to maximum 
concentration;   vss, volume of distribution in steady state.Drug Design, Development and Therapy 2009:3 183
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Special populations
No safety and efficacy data are available for pediatric 
patients and for this reason use is not recommended in this 
population.
In patients over 66 years of age, the mean AUC was 49% 
higher than in nonelderly adults.1 These differences were 
attributed to age-related changes in renal CL. On the other 
hand, no differences were observed in the AUC or in the 
Cmax in terms of the gender of the subjects. Furthermore, 
doripenem’s pharmacokinetics does not seem to be affected 
by the degree of hepatic impairment.1 Hispanics/Latins had 
a CL 14% higher than Caucasian individuals. However, no 
differences were observed with respect to patients of African 
American, or Japanese descent.
renal impairment
Following a single 500-mg dose of doripenem in patients 
with mild (renal CL 50–79 mL/min), moderate (renal CL 
31–50 mL/min), severe (renal CL  30 mL/min), or end-
stage renal impairment, the mean AUC was 1.6, 2.8, 5,1, and 
7.8 times that of healthy subjects with normal renal function.1 
Therefore, dosage adjustment of the antibiotic is necessary 
in patients with a renal CL of 50 mL/min or less. Following 
a four-hour hemodialysis in patients with end-stage renal 
failure who had received a single 500-mg dose of doripenem, 
231 mg of the carbapenem and 28 mg of its metabolite were 
recovered. Despite the fact that, according to these data, 52% 
of doripenem was recovered in the dialysate, there is insuffi-
cient information to make dose-adjustment recommendations 
for patients on hemodialysis.52
Potential drug interactions
Similarly to other carbapenems, one of the most widely 
described drug interaction is that with valproic acid (VA). This 
fact has become evident due to the large number of reports of 
seizures after introducing a carbapenem in patients on stable 
treatment with this antiepilepsy drug. This situation has also 
been observed with doripenem in animal studies.53 However, 
in another study with an animal model, the administration 
of doripenem had no effect on the anticonvulsant activity 
obtained after administering VA in rats with pentilenetetrazol- 
or bicuculline-induced seizures.54
Another widely reported drug interaction is that with 
probenecid, which results in a considerable increase in the 
plasma concentrations of doripenem caused by the inhibition 
of renal tubular secretion.1 Thus, doripenem’s AUC and t1/2 
increased by 75% and 53% respectively when coadministered 
with probenecid.1 Other studies have suggested that the 
combination of carbapenems with vancomycin or teicoplanin 
might improve the antibiotic’s effectiveness against infec-
tions with strains of MRSA.55 Thus, the administration 
of doripenem, panipenem, meropenem, or imipenem was 
synergistic to vancomycin and teicoplanin against more than 
92% and 74% of 27 strains of MRSA from blood cultures. 
Specifically, the combination of doripenem with vancomycin 
was synergistic against 21 (77.8%) strains, while the combi-
nation with teicoplanin was synergistic against 25 (92.6%) 
strains.
Stability and compatibility
In an in vitro study doripenem constituted with water 
(500 mg/10 mL) retained its potency for 60 minutes 
under room conditions without significant loss of its labeled 
potency.56 The 0.9% sodium chloride injection solution 
(5 mg/mL) retained its potency for 12 hours in room 
conditions and 72 hours in refrigeration. The 5% dextrose 
injection solution retained its potency for four hours in 
room conditions and 48 hours in refrigeration. The physical 
compatibility of doripenem diluted for infusion in dextrose 
5% injection or 0.9% sodium chloride injection during 
simulated Y-site administration with 82 other drugs was 
evaluated.57 Doripenem 5 mg/mL in 5% dextrose injection 
and in 0.9% sodium chloride injection was found to be 
compatible with 75/82 (91.5%) of drugs tested for at least 
four hours. However, these solutions were incompatible with 
diazepam, potassium phosphates, and undiluted propofol. 
Doripenem 5 mg/mL in 0.9% sodium chloride injection 
but not in 5% dextrose injection was incompatible with 
amphotericin B-containing drugs.
Clinical efficacy
The clinical trials conducted in the various phases of 
pre-clinical research have focused on the treatment of nosoco-
mial pneumonia (including ventilator-associated pneumonia), 
complicated intra-abdominal infections, and complicated 
urinary tract infections, including pyelonephritis. The results 
of various clinical trials are described below.
Nosocomial pneumonia
Two studies have so far been published that include mostly 
patients with ventilator-associated pneumonia.58,59 The first 
study was designed with the objective of establishing that 
doripenem is not inferior to piperacillin/tazobactam for the 
treatment of nosocomial pneumonia.58 It was a prospective, 
multicenter, randomized, open-label, phase III study that 
included 448 adult patients diagnosed with nosocomial Drug Design, Development and Therapy 2009:3 184
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pneumonia and early ventilator-associated pneumonia 
(5 days on mechanical ventilation). Patients were stratified 
according to the kind of ventilation (spontaneous vs mechani-
cal), APACHE II score, and geographic area. In the study 
group, patients received 500 mg of doripenem intravenously 
every eight hours by one-hour infusion; subjects in the control 
group received piperacillin/tazobactam, 4.5 g every six hours 
by 30-minute infusion. In both groups patients were allowed 
to switch to oral levofloxacin, 750 mg every 24 hours, 
after 72 hours of intravenous treatment. In cases where 
P. aeruginosa was suspected, the simultaneous administration 
of aminoglycosides was allowed. The duration of the 
treatment was 7 to 14 days, depending on clinical progress. 
The assessment of the clinical response was done 7 to 
14 days after completing the study treatment. Doripenem 
was not inferior to piperacillin/tazobactam because in the 
group of clinically evaluable patients (253 patients) there 
were no differences between those treated with doripenem 
and those treated with piperacillin/tazobactam (81.3% vs 
79.8%, respectively), just like among the intent-to-treat 
population (69.6% vs 64.1%, respectively). However, 
piperacillin/tazobactam showed a rate of resistance of 44% 
and 26.9% against Klebsiella pneumoniae and P. aeruginosa 
isolates, respectively, while the resistance to doripenem 
(MIC  8 µg/mL) was of  0% and 7.7% against these 
bacteria. Similarly, the rates of eradication of pathogens 
responsible for nosocomial pneumonia were higher in the 
doripenem arm than in the piperacillin/tazobactam arm, 
although the difference was not significant.58 There were also 
no differences in the adverse effects associated with the study 
medication, which was 16.1% and 17.6% in both groups. In 
another prospective, multicenter, randomized, open-label, 
phase III study, doripenem was compared to imipenem in 
terms of efficacy and tolerability, for the treatment of ventila-
tor-associated pneumonia.59 The objective was to determine 
the noninferiority (differences of less than 20%) of doripenem 
with respect to imipenem for the treatment of this infection. 
Five hundred thirty-one patients from intensive care units 
with clinical and radiological signs of ventilator-associated 
pneumonia were included. The patients were stratified 
according to duration of the mechanical ventilation prior 
to pneumonia (5 days or 5 days), severity according to 
APACHE II (15 or 15), and geographic region. Treatment 
was randomized so that the study arm received doripenem 
500 mg every eight hours by continuous infusion over four 
hours, and the control group received imipenem 500 mg 
every six hours or 1 g every 8 by 30 to 60-minute infusion. 
The duration of the treatment was 7 to 14 days, depending 
on clinical progress. The clinical efficacy was established 
at the end of the treatment in the modified intent-to-treat 
population and in the clinically evaluable population. The 
clinical cure rates at the end of the treatment were 68.3% 
for doripenem, and 64.2% for imipenem in the clinically 
evaluable population, and 59.0% and 57.8%, respectively, 
in the modified intent-to-treat population. In patients with 
ventilator-associated pneumonia caused by P. aeruginosa, the 
rates of cure were 80% for those treated with doripenem, and 
42.9% for those who received imipenem (p:NS). Similarly, 
microbiological eradication was 65.0% and 35.7% for each 
of the treatment arms. In cases with P. aeruginosa, five of 
the 28 (18%) of those treated with doripenem were resistant 
to this antibiotic, while 16 of the 25 (64%) of those treated 
with imipenem were resistant to the antibiotic. The cure 
rates were higher in patients with a higher APACHE II score 
and in those who were older. In the modified intent-to-treat 
population, the presence of 20 (8%) emergent pathogens 
was detected in the doripenem group, and 28 (11%) were 
detected in the imipenem group; in both groups, P. aerugi-
nosa and K. pneumoniae were the most prevalent pathogens. 
There were no differences between the two groups in global 
mortality (10.8% for those treated with doripenem, and 9.5% 
for those with imipenem). The Kaplan–Meier analysis did 
not show differences between both treatment groups in the 
cumulative mortality rate. Among the main limitations in 
pneumonia studies should be emphasized a limited specificity 
of clinical criteria in diagnosis of ventilator-associated pneu-
monia, the need of differentiate early ventilator-associated 
pneumonia versus late ventilator-associated pneumonia and 
the heterogeneous distribution of combined therapy with 
aminoglycosides between groups.60
Complicated intra-abdominal infections
A prospective, multicenter, double-blind, randomized 
study compared the efficacy and tolerability of doripenem 
versus meropenem for the treatment of complicated intra-
abdominal infections in hospitalized adults.61 The objective 
of the study was to show the non-inferiority (less than 15% 
of difference in clinical cure rate) of doripenem for the treat-
ment of these infections compared to meropenem. Patients 
were randomized to receive doripenem, 0.5 g every eight 
hours in a one-hour infusion, or meropenem, 1 g every eight 
hours in bolus over 3–5 minutes. In both study arms the 
association with vancomycin was allowed when there was 
a known or suspected presence of Enterococcus spp. or a 
methicillin-resistant Staphylococcus. The treatment could 
be switched to amoxicillin/clavulanic acid (875/125 mg Drug Design, Development and Therapy 2009:3 185
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every eight hours), after having received nine doses of the 
study treatment (three days), only if progress was favorable. 
Treatment was maintained between 5 and 14 days depending 
on clinical progress. Four hundred seventy-six patients 
were included, who had complicated appendicitis or other 
complicated intra-abdominal infection, including bowel 
perforation, cholecystitis, intra-abdominal abscess, solid 
organ abscess, and generalized peritonitis. The main evalua-
tion criterion was the clinical cure rate in microbiologically 
evaluable patients, which was done in the visit between 21 
and 60 days after completing treatment. The cure rate in 
the 319 microbiologically evaluable patients was 85.9% 
among those treated with doripenem, and 85.3% among 
those treated with meropenem; no other difference was 
found in the different population subgroups analyzed. In 
the intent-to-treat population, severe adverse reactions were 
found in 13.2% and 14.0% of both groups; this caused the 
discontinuation of the drug in 5.1% and 2.1% of the cases, 
respectively. Nor were differences observed in the mortality 
rate, which was very low in both groups (2.1% vs 3.0%). 
The main limitation of this study was the small sample of 
patients who developed postoperative infections in both 
groups. A second, not yet published, study,9 conducted 
with a design identical to the one described above, included 
466 patients with complicated intra-abdominal infection. 
The cure rate in the microbiologically evaluable popula-
tion was 83.3% and 83.0% for doripenem and meropenem, 
respectively.1
Complicated urinary tract infections
Clinical experience with this kind of infection is based on 
two yet unpublished prospective, multicenter, randomized 
studies9 that included 1,179 patients.1 One of the studies was 
double-blind, and compared the administration of doripenem, 
500 mg every eight hours by continuous infusion over one 
hour, to levofloxacin, 250 mg intravenously. Both studies 
allowed the option to switch to oral levofloxacin, 250 mg 
every 24 hours after the intravenous administration of the 
study drugs for three days. The maximum duration of the 
treatment was established in 10 days. Patients with concur-
rent bacteremia were treated with 500 mg of levofloxacin 
(both intravenously and orally), and the treatment was 
maintained for 10 to 14 days. Cure rates in the microbio-
logically evaluable population (isolation of pathogens in the 
baseline cultures) on the visit between the 5th and 11th day 
after completing treatment was 82.1% in those treated with 
doripenem, and 83.4% in those treated with levofloxacin. 
The rates of eradication of pathogens responsible for the 
infections were high, and similar in both treatments for most 
evaluated microorganisms.
Low dose of levofloxacin employed in this study may 
represent a limitation to extrapolate the results in areas 
with high rate of quinolone resistance. The introduction of 
switch therapy from intravenous to oral route constitutes 
an additional limitation in order to evaluate both efficacy 
and safety.
Tolerability
Doripenem’s tolerability profile has been extensively studied 
in various trials. According to the results, doripenem is a well 
tolerated antibiotic, and has been associated with a low inci-
dence of gastrointestinal or central nervous system adverse 
events. Imipenem is the carbapenem most often associated 
with a high risk of seizures, but doripenem, meropenem, and 
ertapenem do not seem to have such a close association, as 
several animal model studies have shown.54,62
One of the most commonly adverse effect reported in 
studies evaluating doripenem is headache, in 33% and 50% 
of patients receiving 500 mg every eight hours and 1000 mg 
every eight hours, respectively, vs 13% of controls.63 Also, 
some gastrointestinal effects such as nausea and diarrhea have 
been reported in 3.7% and 2.5% of patients, respectively.64 
Additionally, the adverse events described in another study 
were mild, and included headache, dyspepsia, and erythema 
at the site of administration.65 The only laboratory abnormal-
ity reported was a moderate elevation of transaminases.
Three out of eight healthy volunteers included in one 
study experienced adverse effects following the administra-
tion of a single dose of 500 mg of doripenem.51 One of the 
subjects had diarrhea, another experienced flatulence, and 
the third had vertigo; however only the first two cases were 
related to the antimicrobial agent. The incidence and type of 
the adverse events were similar in patients with ventilator-
associated pneumonia who received either imipenem 
500 mg every six hours or 1000 mg every eight hours by 
30- or 60-minute continuous infusion, or doripenem 500 mg 
every eight hours in a four-hour intravenous infusion, for a 
period of 7 to 14 days.59 Thus, 17.5% of 263 patients, and 
17.2% of 262 patients receiving imipenem or doripenem 
treatment, respectively, experienced at least one adverse 
event (Table 8). Discontinuation of treatment occurred in 
6% of patients in each group. Only four and five adverse 
events in the imipenem or doripenem groups, respectively, 
were related to the antibiotic given. Additionally, 3.8% of 
patients receiving imipenem had seizures, while this event 
occurred in 1.1% of those receiving doripenem. However, in Drug Design, Development and Therapy 2009:3 186
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all patients, except for one of those receiving imipenem, the 
seizures were not related to the study antibiotic. In another 
prospective, multicenter, randomized study, one of the objec-
tives was to analyze the safety and efficacy of doripenem vs 
piperacillin/tazobactam in patients with nosocomial pneu-
monia.58 In the intent-to-treat analysis, of 223 patients who 
received treatment with doripenem, 67 (30%) experienced 
severe adverse events, while this occurred in 58 (26.2%) 
of the 221 patients who received piperacillin/tazobactam. 
However, none of the events was related to the study antimi-
crobial. Discontinuation of treatment due to adverse events 
occurred in nine (4%) of 223 patients receiving doripenem, 
and in 14 (6.3%) of 221 receiving piperacillin/tazobactam. 
The crude mortality rate was 13.8% (30/217) in the group 
of patients receiving doripenem, and 14.6% (31/212) in the 
group receiving piperacillin/tazobactam.
Study antibiotic-related adverse reactions were observed 
in 36 (16.1%) of 223 patients receiving doripenem and in 
39 (17.6%) of 221 patients receiving piperacillin/tazobactam. 
While an elevation of gamma-glutamyltransferase was the 
most commonly observed adverse effect in the doripenem 
group (2.7%), diarrhea (2.3%) and/or thrombocythemia 
(2.3%) occurred more often in the piperacillin/tazobactam 
group. Additionally, three patients of the doripenem group, 
and six of the piperacillin/tazobactam group had seizures. 
However, the seizures were not related to the study antibiotic 
in any of the cases.
Similarly to previous studies, another study with subjects 
with complicated intra-abdominal infection did not report 
significant differences in the number of patients who expe-
rienced adverse effects following the administration of 
doripenem 500 mg in a one-hour intravenous infusion or 
of meropenem 1 g in bolus, with both antimicrobials being 
prescribed every eight hours.61 Thus, 195 (83%) of the 
235 patients receiving doripenem experienced some kind of 
adverse events, compared to 184 (78%) of the 236 patients 
receiving meropenem. However, the adverse events were 
related to the study antimicrobial in 76 (32.3%) patients 
receiving doripenem and in 63 (26.7%) of those receiving 
meropenem. Among the reactions in both doripenem and 
in meropenem groups were nausea (6.8% vs 1.3%, respec-
tively), and diarrhea (6.4% vs 4.7%).
No patient had seizures as an adverse event. Treatment 
had to be discontinued in five (2.1%) patients receiving 
doripenem, and in three (1.3%) of those receiving merope-
nem, as a result of the development of adverse events related 
to the study antimicrobial. When the severity of the adverse 
events was analyzed, the number of patients who experienced 
severe reactions was not different in the doripenem and the 
meropenem groups (13.2% vs 14%, respectively), but none 
of the events was related to the study drug. The adverse 
events caused the death of 2.1% of patients in the doripenem 
group, compared to 3% of those receiving meropenem. 
The following tables show the adverse events related to the 
Table 8 Antibiotic-related adverse events observed in at least 1% of patients in each treatment group
Adverse event Nosocomial pneumonia Ventilator-associated pneumonia
Réa-Neto et al 200858 Chastre et al 200859
Doripenem 
(n = 223) n (%)
Piperacillin/tazobactam 
(n = 221) n (%)
Doripenem 
(n = 262) n (%)
Imipenem 
(n = 263) n (%)
Patients with at least one  
antibiotic-related adverse event
36 (16.1) 39 (17.6) 45 (17.2) 46 (17.5)
elevated liver enzymes – – 12 (4.6) 6 (2.3)
elevated gamma-glutamyltransferase 6 (2.7) 4 (1.8) – –
elevated alanine aminotransferase 4 (1.8) 2 (0.9) – –
Diarrhea 4 (1.8) 5 (2.3) 5 (1.9) 8 (3.0)
rash – – 5 (1.9) 2 (0.8)
Thrombocytemia 4 (1.8) 5 (2.3)
vomiting – – 4 (1.5) 2 (0.8)
Phlebitis 3 (1.3) 2 (0.9)
elevated aspartate aminotransferase 3 (1.3) 1 (0.5)
elevated eosinophil count 3 (1.3) 1 (0.5)
Nausea – – 3 (1.1) 6 (2.3)
Fungal infection – – 3 (1.1) 1 (0.4%)
impaired liver function – – 2 (0.8) 4 (1.5)Drug Design, Development and Therapy 2009:3 187
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antimicrobial agent observed in 1% of the patients included 
in three phase III clinical trials (Table 9).1
The prevalence of hypersensitivity to carbapenems in 
patients who are allergic to penicillin has been described as 
ranging from 9.2% to 11%.66–68 In general, treatment with 
carbapenems may be considered in patients with a penicillin 
allergy not mediated by immunoglobulin E only if other 
therapeutic alternatives are not available.62 Conversely, 
treatment with these carbapenems should be ruled out if 
the patient has a positive skin test or another documented 
hypersensitivity to penicillin type 1, unless the clinical 
circumstances justify their use.
Pharmacoeconomic considerations
Literature about the pharmacoeconomic aspects of doripenem 
is limited. A subanalysis69 from a randomized clinical 
study comparing doripenem versus imipenem in ventilator-
associated pneumonia59 assessed the use of resources by 
each treatment group. Both patient groups had comparable 
demographic, clinical, and mortality characteristics. The 
median hospital length of stay (LOS) was 22 (95% confidence 
interval [CI]: 20–25) days in the doripenem group, 
and 27 (95% CI: 23–30) days in the imipenem group. 
A comparison between the Kaplan–Meier curves showed 
that the patients receiving doripenem were discharged earlier 
than the patients receiving imipenem (p = 0.010). Similarly, 
fewer days on mechanical ventilation (MV) was observed in 
the group of patients with doripenem compared to the group 
with imipenem (median 7 [95% CI: 6–8] days vs 10 [95% 
CI: 8–11] days, respectively). This result was corroborated 
by Kaplan–Meier curves of the number of days on MV; 
doripenem was associated with a shorter stay compared 
to imipenem (p = 0.034). In contrast, no differences were 
observed in the LOS in intensive care units (ICU) between 
treatment groups (median doripenem 12 [95% CI: 11–13] 
days vs imipenem 13 [95% CI: 12–15] (p = 0.123 by Kaplan–
Meier). Some differences of this study could be attributed to 
the fact that not all LOS was due specifically to ventilator-
associated pneumonia. Some patients with this clinical condi-
tion were admitted to the hospital for other pathologies and 
subsequently acquired ventilator-associated pneumonia as a 
result of mechanical ventilation. Additionally, an analysis was 
Table 9 Study antibiotic-related adverse events observed in at least 1% of patients in each treatment group
Complicated urinary tract infection  
(1 trial)
Complicated intra-abdominal infection 
(2 trials)
Doripenem 
500 mg every 
8 h (n = 376)
Levofloxacin 
250 mg IV every 
24 h (n = 372)
Doripenem 
500 mg every 
8 h (n = 477)
Meropenem 1 g 
every 8 h  
(n = 469)
Nervous system
  Headache 16 15 4 5
Vascular disorders
  Phlebitis 4 4 8 8
Gastrointestinal disorders
  Nausea 4 6 12 9
  Diarrhea 6 10 11 11
Blood and lymph system disorders
 Anemia 2 1 10 5
Kidney and urinary tract disorders
  Kidney impairment/failure 1 0 1 1
Skin and subcutaneous tissue disorders
  Pruritus 1 1 3 2
  rash 1 1 5 2
Lab tests
  elevated liver enzymes 2 3 1 3
Infection
  Oral candidiasis 1 0 1 2
 vulvomycotic infection 2 1 1 1
Notes: Data from Doribax® (doripenem for injection) package insert, 2008.Drug Design, Development and Therapy 2009:3 188
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done with the purpose of evaluating the medical resources 
used by the surviving patients, and thus quantify the effect of 
mortality, if any, on the LOS, the LOS ICU, or the duration 
of the MV. The application of Kaplan–Meier curves showed 
only significant differences in the LOS (p = 0.011); this 
shows a limited effect of mortality on the different use of 
resources between the two treatment groups. Furthermore, 
an analysis was done only in patients with isolated strains 
of P. aeruginosa, with the purpose of evaluating the use 
of resources in the two treatment groups. According to the 
results, no significant differences were observed between 
the 30 patients receiving doripenem and the 26 patients 
receiving imipenem (median LOS 24 [95% CI: 18–36] days 
vs 37 [95% CI: 28–not available] days [p = 0.175]; median 
LOS ICU 15 [95% CI: 9–21] days vs 17 [95% CI: 14–28] days 
[p = 0.195]; median duration of MV 7 [95% CI: 5–9] days 
vs 13 [95% CI: 7–29] days [p = 0.138]).
Following the application of the Cox proportional hazards 
model, doripenem treatment (hazard ratio [HR]: 1.358; 
p = 0.004) and ventilator-associated pneumonia in North 
America (HR: 1.617; p  0.001) were associated with a 
shorter LOS. Additionally, a tendency was observed of an 
association between early initiation of MV and a shorter 
LOS (HR: 1.227; p = 0.058). On the other hand, isolation 
of P. aeruginosa was associated with a longer LOS, but 
this did not reach statistical significance (HR: 0.759; 
p = 0.121). Similarly, treatment with doripenem (HR: 1.145; 
p = 0.149) and having ventilator-associated pneumonia in 
North America (HR: 1.199; p = 0.055), were associated 
with a shorter LOS ICU; however, none of these variables 
reached statistical significance. On the other hand, baseline 
isolation of strains of P. aeruginosa (HR: 0.732; p = 0.035) 
and the baseline APACHE II score (HR: 0.972; p = 0.003) 
were associated with a longer LOS. Finally, treatment with 
doripenem (HR: 1.219; p = 0.049), baseline systolic blood 
pressure (HR: 1.005; p = 0.020), and an APACHE II score 20 
(HR: 1.374; p = 0.011) were associated with a shorter duration 
of MV, while the baseline isolation of strains of P. aeruginosa 
was associated with a longer duration of the MV (HR: 0.805; 
p = 0.170), but not with statistical significance.
Dose and administration
Doripenem is administered exclusively by parenteral route at 
a dose of 500 mg every eight hours, in continuous infusion 
over one hour or over four hours in the case of nosocomial 
pneumonia, in patients over 18 years of age.1,52 Prolonging the 
infusion time has been reported as a more effective strategy than 
dose escalation to increase the PK/PD breakpoint.46 However, 
phase III clinical studies evaluating the administration of 
1, 000 mg infused over four hours every eight hours for hospital-
acquired pneumonia are undergoing clinical evaluation.48 
Dosage in pediatric patients has not been studied yet. In patients 
with impaired renal function, the dose must be adjusted when 
creatinine CL is below 50 mL/min. When creatinine CL is 
30–50 mL/min, administer 250 mg every eight hours, and 
when creatinine CL  30 mL/min, 250 mg every 12 hours. 
Doripenem is eliminated by hemodialysis; however, at present 
there is insufficient information to recommend supplementary 
doses in patients undergoing hemodialysis.1
Doripenem for the treatment  
of severe bacterial infections
Doripenem’s characteristics, which are similar to those 
of currently used carbapenem antibiotics, plus its slightly 
more potency against potentially multiresistant Gram-
negative bacilli, could justify considering it as an alternative 
for multibacterial infections caused by multiresistant 
Gram-negative bacilli. The clinical trials conducted so far 
show an equivalence with respect to the most potent and 
effective first-choice antibiotics. Higher coverage rates 
against P. aeruginosa and K. pneumoniae isolates were 
observed in clinical trials, but without achieving statistical 
differences. Further studies may confirm the impact of treat-
ing infections caused by multidrug-resistant Gram-negative 
microorganisms. The advantages of an adequate empiric 
therapy are well known in the management of critical patients 
with severe infections such as ventilator-associated pneumo-
nia and bacteremia, although the objectives of the studies 
conducted so far have not analyzed this issue.
The indications currently approved by EMEA are the 
treatment of complicated intra-abdominal infections, complicated 
urinary tract infections including pyelonephritis, and the 
treatment of nosocomial pneumonia, regardless of whether it is 
ventilator-associated or not. The studies show an equivalence 
with first-line drugs used so far; thus for these indications, it may 
be an alternative in empirical antimicrobial therapy.
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